CN113905787A - Mettl3抑制化合物 - Google Patents

Mettl3抑制化合物 Download PDF

Info

Publication number
CN113905787A
CN113905787A CN202080040641.3A CN202080040641A CN113905787A CN 113905787 A CN113905787 A CN 113905787A CN 202080040641 A CN202080040641 A CN 202080040641A CN 113905787 A CN113905787 A CN 113905787A
Authority
CN
China
Prior art keywords
methyl
pyridin
imidazo
carboxamide
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080040641.3A
Other languages
English (en)
Chinese (zh)
Inventor
韦斯利·彼得·布莱克比
大卫·詹姆斯·哈迪克
伊丽莎白·简·托马斯
弗雷德里克·亚瑟·布鲁克菲尔德
克里斯蒂安·布伯特
乔恩·谢泼德
马克·彼得·里吉尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Storm Treatment Co ltd
Original Assignee
Storm Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1904848.7A external-priority patent/GB201904848D0/en
Priority claimed from GBGB1912603.6A external-priority patent/GB201912603D0/en
Priority claimed from GBGB1919095.8A external-priority patent/GB201919095D0/en
Application filed by Storm Treatment Co ltd filed Critical Storm Treatment Co ltd
Publication of CN113905787A publication Critical patent/CN113905787A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080040641.3A 2019-04-05 2020-04-03 Mettl3抑制化合物 Pending CN113905787A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1904848.7 2019-04-05
GBGB1904848.7A GB201904848D0 (en) 2019-04-05 2019-04-05 Inhibitory compounds
GBGB1912603.6A GB201912603D0 (en) 2019-09-02 2019-09-02 Inhibitory compounds
GB1912603.6 2019-09-02
GB1919095.8 2019-12-20
GBGB1919095.8A GB201919095D0 (en) 2019-12-20 2019-12-20 Inhibitory compounds
PCT/GB2020/050898 WO2020201773A1 (en) 2019-04-05 2020-04-03 Mettl3 inhibitory compounds

Publications (1)

Publication Number Publication Date
CN113905787A true CN113905787A (zh) 2022-01-07

Family

ID=70285722

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080040641.3A Pending CN113905787A (zh) 2019-04-05 2020-04-03 Mettl3抑制化合物

Country Status (5)

Country Link
US (1) US12358915B2 (enExample)
EP (1) EP3946618A1 (enExample)
JP (1) JP7762957B2 (enExample)
CN (1) CN113905787A (enExample)
WO (1) WO2020201773A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023151697A1 (zh) * 2022-02-11 2023-08-17 四川海思科制药有限公司 一种mettl3抑制剂及组合物及其在医药上的应用
WO2023217109A1 (zh) * 2022-05-13 2023-11-16 中国科学院广州生物医药与健康研究院 m6A RNA甲基化酶抑制剂与免疫检查点抑制剂联合治疗肿瘤
WO2024056099A1 (zh) * 2022-09-16 2024-03-21 北京华益健康药物研究中心 Mettl3抑制剂化合物及其药物组合物和应用

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
IL273428B2 (en) 2017-09-22 2023-09-01 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
BR112020008851A2 (pt) 2017-11-06 2020-10-20 Jubilant Prodel LLC composto da fórmula i, processo de preparação de compostos da fórmula i, composição farmacêutica, método para o tratamento e/ou prevenção de várias doenças, uso, método para o tratamento de câncer, método de tratamento de câncer e método para o tratamento e/ou prevenção de câncer e doenças infecciosas
JP7368369B2 (ja) 2017-11-24 2023-10-24 ジュビラント・エピスクライブ・エルエルシー Ｐｒｍｔ５阻害剤としてのヘテロ環式化合物
JP7279063B6 (ja) 2018-03-13 2024-02-15 ジュビラント プローデル エルエルシー Ｐｄ１／ｐｄ－ｌ１相互作用／活性化の阻害剤としての二環式化合物
TWI833819B (zh) 2018-10-05 2024-03-01 美商安尼波那生物公司 用於治療與apj受體活性相關的病狀的化合物及組成物
BR112022010561A2 (pt) * 2019-12-02 2022-11-16 Storm Therapeutics Ltd Compostos poli-heterocíclicos como inibidores de mettl3
WO2022074379A1 (en) * 2020-10-06 2022-04-14 Storm Therapeutics Limited Mettl3 inhibitory compounds
US11944608B2 (en) * 2020-10-26 2024-04-02 New York University Targeting RNA viruses using inhibitors of METTL3
WO2022243333A1 (en) * 2021-05-17 2022-11-24 Universität Zürich N6-adenosine-methyltransferase inhibitors in cancer treatment
GB202107907D0 (en) * 2021-06-02 2021-07-14 Storm Therapeutics Ltd Combination therapies
GB202107905D0 (en) * 2021-06-02 2021-07-14 Storm Therapeutics Ltd Processes for the preparation of inhibitory compounds
WO2023104209A1 (zh) * 2021-12-10 2023-06-15 上海昂阔医药有限公司 Mettl3抑制剂化合物
CN114869891A (zh) * 2022-04-28 2022-08-09 复旦大学附属中山医院 Mettl3抑制剂在制备治疗肝癌药物中的应用
WO2024107763A1 (en) * 2022-11-16 2024-05-23 University Of Zurich N6-adenosine-methyltransferase protacs and methods of use thereof
GB202218672D0 (en) 2022-12-12 2023-01-25 Storm Therapeutics Ltd Inhibitory compounds
KR20250135296A (ko) 2023-01-20 2025-09-12 에픽스 테라퓨틱스 Mettl3 억제제로서의 피페리딘 유도체
WO2024200835A1 (en) 2023-03-30 2024-10-03 Novalix Novel mettl3 inhibitors and use thereof in therapy
GB202316683D0 (en) * 2023-10-31 2023-12-13 Storm Therapeutics Ltd Inhibitory compounds
WO2025237957A1 (en) 2024-05-14 2025-11-20 Institut Curie Composition for treatment of estrogen-dependent cancer comprising a mettl-3 inhibitor and a topoisomerase-1 inhibitor

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3946031A (en) * 1973-10-04 1976-03-23 Syntex Inc. 2-Substituted-1,2,4-thiadiazolo-[2,3-a]-benzimidazoles
WO2002044156A2 (en) * 2000-11-29 2002-06-06 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
WO2007095588A1 (en) * 2006-02-14 2007-08-23 Novartis Ag Pi-3 kinase inhibitors and methods of their use
US20090163488A1 (en) * 2007-06-05 2009-06-25 Takeda Pharmaceutical Company Limited Fused heterocycle derivatives and use thereof
WO2009106749A2 (fr) * 2008-01-02 2009-09-03 Sanofi-Aventis Dérivés de n-heterocyclique-imidazo[1,2-a]pyridine-2-carboxamides, leur préparation et leur application en thérapeutique
US20100029619A1 (en) * 2006-08-04 2010-02-04 Takeda Pharmaceutical Company Limted Fused heterocyclic compound

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3880874A (en) * 1973-10-04 1975-04-29 Syntex Inc 2-Substituted -1,2,4-thiadiazolo-(2,3-a)benzimidazoles and process for their preparation
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab, Soedertaelje 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
WO2001010380A2 (en) 1999-08-04 2001-02-15 Icagen, Inc. Benzanilides as potassium channel openers
DE19936780A1 (de) 1999-08-09 2001-02-15 Basf Ag Neue Antagonisten von Integrinrezeptoren
CN1431999A (zh) 2000-05-31 2003-07-23 阿斯特拉曾尼卡有限公司 具有血管损伤活性的吲哚衍生物
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
JP2004502766A (ja) 2000-07-07 2004-01-29 アンギオジェン・ファーマシューティカルズ・リミテッド 血管損傷剤としてのコルヒノール誘導体
RU2003103603A (ru) 2000-07-07 2004-08-20 Энджиоджен Фармасьютикалз Лимитед (Gb) Производные колхинола в качестве ингибиторов ангиогенеза
CA2464419A1 (en) 2001-11-09 2003-05-22 Boehringer Ingelheim Pharmaceuticals, Inc. Benzimidazoles useful as protein kinase inhibitors
AU2011229423B2 (en) 2010-03-18 2015-12-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-infective compounds
US20200129596A1 (en) 2017-03-13 2020-04-30 City Of Hope m6A mRNA MODIFICATION IN CANCER TREATMENT
BR112022010561A2 (pt) * 2019-12-02 2022-11-16 Storm Therapeutics Ltd Compostos poli-heterocíclicos como inibidores de mettl3

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3946031A (en) * 1973-10-04 1976-03-23 Syntex Inc. 2-Substituted-1,2,4-thiadiazolo-[2,3-a]-benzimidazoles
WO2002044156A2 (en) * 2000-11-29 2002-06-06 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
WO2007095588A1 (en) * 2006-02-14 2007-08-23 Novartis Ag Pi-3 kinase inhibitors and methods of their use
US20100029619A1 (en) * 2006-08-04 2010-02-04 Takeda Pharmaceutical Company Limted Fused heterocyclic compound
US20090163488A1 (en) * 2007-06-05 2009-06-25 Takeda Pharmaceutical Company Limited Fused heterocycle derivatives and use thereof
WO2009106749A2 (fr) * 2008-01-02 2009-09-03 Sanofi-Aventis Dérivés de n-heterocyclique-imidazo[1,2-a]pyridine-2-carboxamides, leur préparation et leur application en thérapeutique

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"(6-Chloroimidazo[1, 2-a]pyridin-2-yl)methyl 5-bromo-3-pyridinecarboxylate", REGISTRY数据库（STN）, pages 1 *
"(6-Chloroimidazo[1, 2-a]pyridin-2-yl)methyl 6-chloro-3-pyridinecarboxylate", REGISTRY数据库（STN）, pages 1 *
"(6-Chloroimidazo[1, 2-a]pyridin-2-yl)methyl 6-methyl-3-pyridinecarboxylate", REGISTRY数据库（STN）, pages 1 *
"(6-Methylimidazo[1, 2-a]pyridin-2-yl)methyl 5-bromo-3-pyridinecarboxylate", REGISTRY数据库（STN）, pages 1 *
"(6-Methylimidazo[1, 2-a]pyridin-2-yl)methyl 6-methyl-3-pyridinecarboxylate", REGISTRY数据库（STN）, pages 1 *
"2-[2-[3-(3-Pyridinyl)-1, 2, 4-oxadiazol-5-yl]ethyl]imidazo[1, 2-a]pyridine", REGISTRY数据库（STN）, pages 1 *
"5-Bromo-N-(2-imidazo[1, 2-a]pyridin-2-ylethyl)-3-pyridinecarboxamide", REGISTRY数据库（STN）, pages 1 *
"5-Bromo-N-(imidazo[1, 2-a]pyridin-2-ylmethyl)-3-pyridinecarboxamide", REGISTRY数据库（STN）, pages 1 *
"N-(2-Imidazo[1, 2-a]pyridin-2-ylethyl)-6-methyl-3-pyridinecarboxamide", REGISTRY数据库（STN）, pages 1 *
"N-(Imidazo[1, 2-a]pyridin-2-ylmethyl)-6-methyl-3-pyridinecarboxamide", REGISTRY数据库（STN）, pages 1 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023151697A1 (zh) * 2022-02-11 2023-08-17 四川海思科制药有限公司 一种mettl3抑制剂及组合物及其在医药上的应用
WO2023217109A1 (zh) * 2022-05-13 2023-11-16 中国科学院广州生物医药与健康研究院 m6A RNA甲基化酶抑制剂与免疫检查点抑制剂联合治疗肿瘤
WO2024056099A1 (zh) * 2022-09-16 2024-03-21 北京华益健康药物研究中心 Mettl3抑制剂化合物及其药物组合物和应用

Also Published As

Publication number Publication date
US12358915B2 (en) 2025-07-15
JP7762957B2 (ja) 2025-10-31
JP2022528562A (ja) 2022-06-14
US20230085408A1 (en) 2023-03-16
WO2020201773A1 (en) 2020-10-08
EP3946618A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
CN113905787A (zh) Mettl3抑制化合物
US12077536B2 (en) BCL-2 inhibitors
CN115151540A (zh) 作为mettl3抑制剂的多杂环化合物
JP6496376B2 (ja) 阻害剤化合物
CN111918651B (zh) Gcn2抑制剂及其用途
EP2534151B1 (en) 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds
CN104125959B (zh) 作为btk活性的抑制剂的杂芳基吡啶酮和氮杂‑吡啶酮化合物
CN115485278A (zh) 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶(btk)及其使用方法
CN112166110A (zh) Shp2磷酸酶抑制剂及其使用方法
CN109983001A (zh) 作为变构shp2抑制剂的2,5-双取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪
AU2012228090A1 (en) Pyrrolopyridineamino derivatives as Mps1 inhibitors
CA2911051A1 (en) Biheteroaryl compounds and uses thereof
CN111655695B (zh) 作为pde1抑制剂的取代的呋喃并嘧啶化合物
CN115996929A (zh) 腺苷A2a受体的拮抗剂
JP2020537671A (ja) ピリミジンＴＢＫ／ＩＫＫεインヒビター化合物およびそれらの使用
US20240034731A1 (en) Aza-quinazoline compounds and methods of use
CN113683629B (zh) 取代的杂芳基化合物及其组合物和用途
US20250388577A1 (en) Mettl3 inhibitory compounds
KR20250135296A (ko) Mettl3 억제제로서의 피페리딘 유도체
CN115557946A (zh) 杂环内酰胺类化合物，包含其的药物组合物及其用途
HK40074720A (en) [1,2,4]triazolo[1,5-c]quinazolin-5-amines
HK40044087A (en) Shp2 phosphatase inhibitors and methods of use thereof
EA043978B1 (ru) ИНГИБИТОРЫ Bcl-2
HK40039599A (en) Gcn2 inhibitors and uses thereof
HK40044087B (zh) Shp2磷酸酶抑制剂及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination